default author photo

Matteo Lambertini

University of Genova - Department of Internal Medicine and Medical Specialties (DiMI)

Genova

Italy

SCHOLARLY PAPERS

5

DOWNLOADS

334

TOTAL CITATIONS

0

Scholarly Papers (5)

1.

Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis

Number of pages: 35 Posted: 13 Jun 2025
Scuola Superiore Meridionale, Vanvitelli University of Campania Luigi Vanvitelli, University of Naples Federico II, Baylor College of Medicine, University of Milan, University of Padova, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Sapienza University of Rome, Baylor College of Medicine, Harvard University - Dana-Farber Cancer Institute, University of Naples Federico II, University of Naples Federico II, University of Naples Federico II, Fondazione IRCCS Istituto Nazionale dei Tumori, Gustave Roussy, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda USL Toscana Centro - Sandro Pitigliani Translational Research Unit, University of Udine - Deparment of Medicine (DAME), University of Naples Federico II, Vanvitelli University of Campania Luigi Vanvitelli, IRCCS-Fondazione Bietti and Baylor College of Medicine
Downloads 146 (505,974)

Abstract:

Loading...

HR+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, Systematic Review, Network meta-analysis, Biomarker-driven therapy, Antibody-drug conjugates

2.

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Number of pages: 34 Posted: 12 Sep 2025
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Università di Padova - Dipartimento di Scienze Chirurgiche, European Institute of Oncology (IEO) IRCCS - Division of New Drugs and Early Drug Development for Innovative Therapies, Baylor College of Medicine, Sapienza University of Rome, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Fondazione IRCCS Policlinico San Matteo, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, ASST Papa Giovanni XXIII, affiliation not provided to SSRN, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Azienda Socio Sanitaria Territoriale Lariana, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Istituto Nazionale dei Tumori
Downloads 52 (1,041,696)

Abstract:

Loading...

HR+/HER2- advanced breast cancer, CDK4/6 inhibitors, Real-world, progression-free survival, Lobular histology, PALMARES-2

3.

Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy

Number of pages: 22 Posted: 16 Jul 2025
Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - University Hospitals Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Gothenburg - Sahlgrenska University Hospital, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), affiliation not provided to SSRN, affiliation not provided to SSRN, Université de Lille - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Institute of Oncology, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Santa Maria Local Health Unit, affiliation not provided to SSRN, affiliation not provided to SSRN, HFR Fribourg Cantonal Hospital, Bank of Cyprus Oncology Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), Istinye University, Maastricht University, AZ Turnhout, AZ Groeninge, Hebrew University of Jerusalem - Shaare Zedek Medical Center, affiliation not provided to SSRN, Hebrew University of Jerusalem - The Sharett Institute of Oncology, IRCCS Ospedale Policlinico San Martino, Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - Department of Gynecologic Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Technion-Israel Institute of Technology - Rambam Health Care Campus, affiliation not provided to SSRN, Istinye University, European Commission, Joint Research Centre and Netherlands Cancer Institute
Downloads 52 (1,041,696)

Abstract:

Loading...

Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response

4.

The Rising Burden of Contraception Requirements in Breast Cancer Clinical Trials: Time for Change?

Number of pages: 10 Posted: 17 Oct 2023
Cork University Hospital, Cork University Hospital, Cork University Hospital, Gustave Roussy, University of Lausanne - Lausanne University Hospital, University of Liverpool, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Gustave Roussy - Breast Cancer Unit and Cork University Hospital
Downloads 45 (1,121,190)

Abstract:

Loading...

Breast Cancer, Clinical Trials, Contraception, Quality of Life

5.

Comparison of Suboptimal Versus Adequate Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer Treated with Adjuvant Endocrine Therapy: An Exploratory Analysis of Two Prospective Studies

Number of pages: 23 Posted: 06 Aug 2025
IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino - Clinical Epidemiology Unit, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, University of Naples Federico II, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, University of Paris-Saclay - INSERM Unit 981, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, affiliation not provided to SSRN, IRCCS Ospedale Policlinico San Martino, affiliation not provided to SSRN, IRCCS Ospedale Policlinico San Martino, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), University of Genova - Department of Internal Medicine and Medical Specialties (DiMI) and IRCCS Ospedale Policlinico San Martino
Downloads 39 (1,196,171)

Abstract:

Loading...

Gonadotropin-releasing hormone agonist, Hormone receptor-positive early breast cancer, Aromatase Inhibitor, Ovarian Suppression, Adjuvant endocrine treatment, Premenopausal